|
|
 |
|
|
|
|
Factoid of the Day
|
Friday, April 10, 2026
|
|
The U.S. Food and Drug Administration (FDA) reported that it approved ten new drugs in the first quarter of 2026, up from seven over the same period in 2025. For comparison, the FDA approved only six new drugs in the first quarter of 2018 but reached a record 59 approvals by the end of the year.
|
|
First Trust Target Outcome ETFs®
|
| |
Upcoming Unit Investment Trusts |
Initial Offer Date |
| • |
40/60 Strategic Allocation, 2nd Qtr 2026 |
4/13/2026 |
| • |
60/40 Strategic Allocation, 2nd Qtr 2026 |
4/13/2026 |
| • |
75/25 Strategic Allocation, 2nd Qtr 2026 |
4/13/2026 |
| • |
Diversified Fixed Income ETF, 67 |
4/13/2026 |
| • |
Vest Large Cap Buffered 10, 98 |
4/14/2026 |
| • |
Vest Small Cap Buffered 20, 21 |
4/14/2026 |
| • |
Dividend & Income Select Closed-End, 119 |
4/15/2026 |
| • |
Equity Income Opportunity, 37 |
4/15/2026 |
| • |
REIT Growth & Income Select, 76 |
4/15/2026 |
| • |
Strategic Income Closed-End, 111 |
4/15/2026 |
| • |
U.S. Equity Closed-End, 57 |
4/15/2026 |
| • |
Vest Large Cap Deep Buffered 20, 105 |
4/16/2026 |
| • |
Cloud Computing, 53 |
4/17/2026 |
| • |
Cyclical Strength, 54 |
4/17/2026 |
| • |
Sabrient Baker's Dozen, 2nd Qtr 2026 |
4/17/2026 |
| • |
Select DSIP, 2nd Qtr 2026 |
4/17/2026 |
| • |
Vest Nasdaq 100 Buffered 10, 30 |
4/20/2026 |
| • |
FT Diversified Target Income, 14 |
4/21/2026 |
| • |
Limited Duration Fixed Income ETF, 69 |
4/21/2026 |
| • |
Capital Strength Opportunity, 42 |
4/22/2026 |
|
|
|
|
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|